What Makes Bio-Techne Corporation (TECH) a Good Investment?
Madison Investments, an investment advisor, released its fourth-quarter 2025 investor letter for “Madison Mid Cap Fund”. A copy of the letter can be downloaded here.
Bio-Techne Corp (TECH)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bayforest Capital Theodoros Tsagaris | 154 | $8,048 | +340% | 0.01% |
| 2. | Sivik Global Healthcare Krishen Sud | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $352.55 | 300 | $105,765.00 | 10,106 | 2022-05-10 | Filing | |
| $185.00 | 100 | $18,500.00 | 100 | 2019-09-09 | Filing | |
| $185.00 | 100 | $18,500.00 | 100 | 2019-09-09 | Filing | |
| $191.06 | 500 | $95,530.00 | 8,726 | 2019-08-07 | Filing | |
| $65.00 | 2,361 | $153,465.00 | 70,000 | 2013-05-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $59.11 | 1,976 | $116,791.48 | 200 | 2026-02-17 | Filing | |
| $56.36 | 17,040 | $960,388.03 | 44,559 | 2025-08-25 | Filing | |
| $56.21 | 17,040 | $957,818.40 | 44,863 | 2025-08-25 | Filing | |
| $49.77 | 1,280 | $63,704.83 | 1,976 | 2025-06-09 | Filing | |
| $65.96 | 1,860 | $122,690.62 | 1,976 | 2025-02-14 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 608,916 | $31,821,951 | 0.78% | |
| 2. | 451,416 | $23,591,000 | 0.47% | |
| 3. | 360,913 | $18,861,313 | 0.1% | |
| 4. | 55,524 | $2,901,685 | 0.29% | |
| 5. | 47,921 | $2,504,352 | 0.03% |
News See All
Bio-Techne Corporation (TECH) Carries Attractive FY27 Organic Growth Projections
On February 5, Daniel Arias from Stifel Nicolaus reaffirmed his Hold rating on Bio-Techne Corporation (NASDAQ:TECH).
10 Best Life Sciences Stocks to Buy According to Hedge Funds
Following a difficult start in 2025, the ever-evolving life sciences segment recovered strongly in the latter half of the year.
Bio-Techne Corporation (NASDAQ:TECH) Q2 2026 Earnings Call Transcript
Operator: To all sites on hold, thank you for your continued patience. Your meeting will begin shortly.
Here’s Why BioTechne (TECH) Traded Lower in Q3
Mairs & Power, an investment advisor, released the third-quarter 2025 investor letter for the “Mairs & Power Balanced Fund.” A copy of the letter can be downloaded here.
Bio-Techne Corporation (TECH): A Bull Case Theory
We came across a bullish thesis on Bio-Techne Corporation on Valueinvestorsclub.com by rab. In this article, we will summarize the bulls’ thesis on TECH.
Is Bio-Techne Corporation (TECH) a High-Quality Growth-Oriented Compounder Within The Healthcare Sector?
ClearBridge Investments, an investment management company, released its “ClearBridge Mid Cap Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Bio-Techne Corporation (NASDAQ:TECH) Q1 2026 Earnings Call Transcript
Operator: Good morning, and welcome to the Bio-Techne Earnings Conference Call for the First Quarter of Fiscal Year 2026.
BioTechne (TECH) Fell Over the Industry’s Uncertain Funding Environment
Mairs & Power, an investment advisor, released the “Mairs & Power Balanced Fund” second quarter 2025 investor letter. A copy of the letter can be downloaded here.
Here’s Why The Brown Capital Small Company Fund is Re-Evaluating Bio-Techne’s (TECH) Long-Term Growth Profile
Brown Capital Management, an investment management company, released its “The Brown Capital Management Small Company Fund” second quarter 2025 investor letter.
Hedge Fund Resource Center